Olema Pharmaceuticals Inc (OLMA) Stock Price, Quote & News

Company Profile

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivota...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 651 3316

Website: olema.com

Address:

780 Brannan Street, San Francisco, United States

Keystone1 Mar. 17 at 7:04 PM

$OLMA Hopefully it recovers this afternoon!

0 · Reply

patatechaude Mar. 17 at 4:08 PM

$OLMA Stopped out. It'll go up now.

1 · Reply

Merlintrader Mar. 17 at 3:35 PM

$OLMA

0 · Reply

Keystone1 Mar. 17 at 1:45 PM

$OLMA Little profit taking after a 13% gain. Wouldn’t surprise me if it closes green, especially so on St. Patrick’s day!

0 · Reply

patatechaude Mar. 17 at 12:20 PM

$XBI $OLMA Completely under the radar. Breast cancel drug could make this little gem a multi-billion revenue biotech.

0 · Reply

Keystone1 Mar. 17 at 11:25 AM

$OLMA https://finance.yahoo.com/news/biotech-stock-nearly-300-draws-230212645.html

0 · Reply

Merlintrader Mar. 17 at 7:02 AM

$OLMA https://www.merlintrader.com/olema-pharmaceuticals-inc-march17-dd/

0 · Reply

toxicdogie Mar. 16 at 10:16 PM

$BMNR $NCPL $OLMA $ORBS NCPL watch for a massive splice overnight and tmrw 50-60%++

0 · Reply

_SilverFoxTrail Mar. 16 at 8:50 PM

{}@SqueezeSharkie is on a different level, ahead of 90% of traders on this platform. If you’re not following yet, you’re missing out. Takes 2 seconds and it’s free💎 $ORBS $BMNR $OLMA $NCPL >> on watch as well..

0 · Reply

rayTrade81 Mar. 16 at 7:58 PM

$OLMA biotech under the radar setup with asymmetry improving if buyers show up with size

0 · Reply

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mar 9, 2026, 1:57 PM EDT - 8 days ago

Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA

Mar 9, 2026, 12:22 PM EDT - 8 days ago

Why Is Olema Pharmaceuticals Stock Dropping On Monday?

Mar 3, 2026, 4:30 PM EST - 14 days ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 23, 2026, 12:04 PM EST - 22 days ago

Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Feb 13, 2026, 4:47 PM EST - 4 weeks ago

Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Feb 4, 2026, 4:30 PM EST - 5 weeks ago

Olema Oncology to Participate in Upcoming Investor Conferences

Jan 30, 2026, 4:01 PM EST - 6 weeks ago

Olema Oncology Announces Departure of Chief Operating and Financial Officer

Jan 22, 2026, 10:26 AM EST - 7 weeks ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 15, 2026, 12:05 PM EST - 2 months ago

Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 5, 2026, 7:00 AM EST - 2 months ago

Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 24, 2025, 9:00 AM EST - 2 months ago

Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal

Nov 21, 2025, 4:30 PM EST - 4 months ago

Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

Nov 20, 2025, 4:01 PM EST - 4 months ago

Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Nov 18, 2025, 4:51 PM EST - 4 months ago

Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 18, 2025, 4:21 PM EST - 4 months ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN JNJ LLY MDT MRK NVO PFE

Nov 18, 2025, 12:01 PM EST - 4 months ago

Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock

Nov 18, 2025, 10:21 AM EST - 4 months ago

OLMA stock: could today's 197% surge be just the beginning?

Nov 18, 2025, 9:56 AM EST - 4 months ago

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Nov 10, 2025, 7:00 AM EST - 4 months ago

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Oct 30, 2025, 4:30 PM EDT - 4 months ago

Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

Oct 30, 2025, 3:25 PM EDT - 4 months ago

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Oct 18, 2025, 3:00 AM EDT - 5 months ago

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Sep 2, 2025, 7:00 AM EDT - 7 months ago

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

PFE

Aug 11, 2025, 4:01 PM EDT - 7 months ago

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

May 28, 2025, 7:00 AM EDT - 10 months ago

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

May 13, 2025, 4:01 PM EDT - 11 months ago

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

Apr 25, 2025, 1:00 PM EDT - 11 months ago

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Apr 8, 2025, 4:25 PM EDT - 1 year ago

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Mar 25, 2025, 4:31 PM EDT - 1 year ago

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Mar 18, 2025, 4:01 PM EDT - 1 year ago

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 7:00 AM EST - 1 year ago

Olema Oncology Appoints Shawnte M. Mitchell, J.D.

Jan 2, 2025, 7:00 AM EST - 1 year ago

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 7:46 AM EST - 1 year ago

Top 3 Health Care Stocks That May Explode In Q4

SLN

Dec 10, 2024, 7:00 AM EST - 1 year ago

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Dec 9, 2024, 7:00 AM EST - 1 year ago

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Nov 25, 2024, 5:30 PM EST - 1 year ago

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Nov 12, 2024, 4:01 PM EST - 1 year ago

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 28, 2024, 7:03 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in June

May 15, 2024, 7:01 AM EDT - 1 year ago

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

May 8, 2024, 4:02 PM EDT - 2 years ago

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 7:02 AM EDT - 2 years ago

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

May 1, 2024, 7:02 AM EDT - 2 years ago

Olema Oncology to Participate in Upcoming Investor Conferences in May

Apr 8, 2024, 4:30 PM EDT - 2 years ago

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Mar 11, 2024, 4:03 PM EDT - 2 years ago

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 7:03 AM EST - 2 years ago

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Keystone1 Mar. 17 at 7:04 PM

$OLMA Hopefully it recovers this afternoon!

0 · Reply

patatechaude Mar. 17 at 4:08 PM

$OLMA Stopped out. It'll go up now.

1 · Reply

Merlintrader Mar. 17 at 3:35 PM

$OLMA

0 · Reply

Keystone1 Mar. 17 at 1:45 PM

$OLMA Little profit taking after a 13% gain. Wouldn’t surprise me if it closes green, especially so on St. Patrick’s day!

0 · Reply

patatechaude Mar. 17 at 12:20 PM

$XBI $OLMA Completely under the radar. Breast cancel drug could make this little gem a multi-billion revenue biotech.

0 · Reply

Keystone1 Mar. 17 at 11:25 AM

$OLMA https://finance.yahoo.com/news/biotech-stock-nearly-300-draws-230212645.html

0 · Reply

Merlintrader Mar. 17 at 7:02 AM

$OLMA https://www.merlintrader.com/olema-pharmaceuticals-inc-march17-dd/

0 · Reply

toxicdogie Mar. 16 at 10:16 PM

$BMNR $NCPL $OLMA $ORBS NCPL watch for a massive splice overnight and tmrw 50-60%++

0 · Reply

_SilverFoxTrail Mar. 16 at 8:50 PM

0 · Reply

rayTrade81 Mar. 16 at 7:58 PM

$OLMA biotech under the radar setup with asymmetry improving if buyers show up with size

0 · Reply

patatechaude Mar. 16 at 7:27 PM

$XBI Nobody’s talking about $OLMA yet but they’re potentialy the next big name for breast cancer. I wouldn’t be surprised to see them being acquired for $40-$50 share. They’re at $16 today.

1 · Reply

topstockalerts Mar. 16 at 5:45 PM

$OLMA Buyers stepping in with conviction. Price responds quickly to demand. That’s what strong trends look like 💪.

0 · Reply

Keystone1 Mar. 16 at 3:35 PM

$OLMA Good day for the bulls! Would love to see some 10-20% daily gains. Oversold and due for recovery.

0 · Reply

patatechaude Mar. 16 at 3:03 PM

$OLMA $500M in the bank. Potentially the new leader in breast cancer. $30 is coming fast. $XBI

0 · Reply

Keystone1 Mar. 16 at 1:49 PM

$OLMA Good to see the nice pop today. Perhaps the bottom is in!

0 · Reply

Keystone1 Mar. 16 at 11:56 AM

$OLMA https://finance.yahoo.com/news/olema-oncology-reports-fourth-quarter-110000675.html

0 · Reply

Keystone1 Mar. 11 at 4:47 PM

$OLMA Probably trying to read the tea leaves, but it was interesting to see the stock go green by 2% when the overall market was down.

1 · Reply

MadMaverick Mar. 11 at 3:22 AM

⚡WATCHLIST RECAP 03/09/26⚡ ✅ $OLMA | +40% max profit ✅ $AZI | +58% max profit ✅ $LRHC | +15% max profit $BURU did not hit entry.

0 · Reply

patatechaude Mar. 10 at 7:23 PM

$CAPR 98% of my portfolio is in CAPR. 2% in $OLMA (I doubled my OLMA position yesterday). Capricor has not even started rising. $200 is totally possible.

2 · Reply

Keystone1 Mar. 10 at 3:40 PM

$OLMA https://finance.yahoo.com/news/h-c-wainwright-does-not-152013614.html

0 · Reply

patatechaude Mar. 10 at 2:39 PM

$OLMA The market is waking up to the fact that OLMA is now alone and could have the breast cancer market to themselves. Will Roche try to acquire them? $XBI

0 · Reply

WallStreetBuyDip Mar. 10 at 8:14 AM

$OLMA Trading at $16.00, quite a range between the highest of $35.83 and lowest of $3.06. Recent volume on Mar 9, 2026, spiked to 13.9M, significantly above the average volume of 1.7M.

0 · Reply

Market Cap	1.01B
Revenue (ttm)	0.00
Net Income (ttm)	-129.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.01

Volume	1,595,490
Avg Vol	1,636,380
Day's Range	N/A - N/A
Shares Out	68.66M
Stochastic %K	31%
Beta	1.92
Analysts	Strong Sell
Price Target	$43.73